[1] 中国心血管病风险评估和管理指南[J]. 中国循环杂志, 2019, 34(1): 4-28. [2] Otsuka F, Yasuda S, Noguchi T, et al. Pathology of coronary atherosclerosis and thrombosis[J]. Cardiovasc Diagn Ther, 2016, 6(4): 396-408. [3] Williams JW, Giannarelli C, Rahman A, et al. Macrophage biology, classification, and phenotype in cardiovascular disease: JACC macrophage in CVD series (Part 1)[J]. J Am Coll Cardiol, 2018, 72(18): 2166-2180. [4] Cao DJ. Macrophages in cardiovascular homeostasis and disease[J]. Circulation, 2018, 138(22): 2452-2455. [5] Tabas I, Bornfeldt KE. Macrophage phenotype and function in different stages of atherosclerosis[J]. Circ Res, 2016, 118(4): 653-667. [6] Tempé D, Vives E, Brockly F, et al. SUMOylation of the inducible (c-Fos:c-Jun)/AP-1 transcription complex occurs on target promoters to limit transcriptional activation[J]. Oncogene, 2014, 33(7): 921-927. [7] Caputto BL, Cardozo Gizzi AM, Gil GA. c-Fos: an AP-1 transcription factor with an additional cytoplasmic, non-genomic lipid synthesis activation capacity[J]. Biochim Biophys Acta, 2014, 1841(9): 1241-1246. [8] Friedman AD. Transcriptional control of granulocyte and monocyte development[J]. Oncogene, 2007, 26(47): 6816-6828. [9] Liu H, Lorenzini PA, Zhang F, et al. Alternative splicing analysis in human monocytes and macrophages reveals MBNL1 as major regulator[J]. Nucleic Acids Res, 2018, 46(12): 6069-6086. [10] Genin M, Clement F, Fattaccioli A, et al. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide[J]. BMC Cancer, 2015, 15: 577. [11] Gharib SA, McMahan RS, Eddy WE, et al. Transcriptional and functional diversity of human macrophage repolarization[J]. J Allergy Clin Immunol, 2019, 143(4): 1536-1548. [12] Koelwyn GJ, Corr EM, Erbay E, et al. Regulation of macrophage immunometabolism in atherosclerosis[J]. Nat Immunol, 2018, 19(6): 526-537. [13] Ganta VC, Choi MH, Kutateladze A, et al. A microRNA93-Interferon regulatory factor-9-immunoresponsive gene-1-itaconic acid pathway modulates M2-like macrophage polarization to revascularize ischemic muscle[J]. Circulation, 2017, 135(24): 2403-2425. [14] Chen HH, Keyhanian K, Zhou X, et al. IRF2BP2 reduces macrophage inflammation and susceptibility to atherosclerosis[J]. Circ Res, 2015,117(8): 671-683. [15] Ko KR, Lee J, Nho B, et al. c-Fos is necessary for HGF-mediated gene regulation and cell migration in Schwann cells[J]. Biochem Biophys Res Commun, 2018, 503(4): 2855-2860. [16] Motomura H, Seki S, Shiozawa S, et al. A selective c-Fos/AP-1 inhibitor prevents cartilage destruction and subsequent osteophyte formation[J]. Biochem Biophys Res Commun, 2018, 497(2): 756-761. |